Lisa Abuogi
Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 59 | 2026 | 3215 | 8.960 |
Why?
| | Anti-HIV Agents | 27 | 2026 | 914 | 7.030 |
Why?
| | Infectious Disease Transmission, Vertical | 24 | 2026 | 188 | 6.160 |
Why?
| | Kenya | 37 | 2026 | 129 | 4.330 |
Why?
| | Pregnancy Complications, Infectious | 15 | 2026 | 438 | 3.270 |
Why?
| | Anti-Retroviral Agents | 10 | 2026 | 250 | 2.810 |
Why?
| | Viral Load | 14 | 2026 | 526 | 2.640 |
Why?
| | Breast Feeding | 10 | 2026 | 447 | 2.330 |
Why?
| | Sexual Partners | 9 | 2026 | 195 | 1.860 |
Why?
| | Sustained Virologic Response | 2 | 2026 | 48 | 1.480 |
Why?
| | Pregnancy | 31 | 2026 | 7230 | 1.410 |
Why?
| | Intimate Partner Violence | 4 | 2025 | 93 | 1.350 |
Why?
| | Medication Adherence | 7 | 2025 | 535 | 1.320 |
Why?
| | Qualitative Research | 8 | 2026 | 1734 | 1.320 |
Why?
| | Text Messaging | 4 | 2023 | 188 | 1.310 |
Why?
| | Infant | 29 | 2026 | 10114 | 1.180 |
Why?
| | Social Stigma | 10 | 2026 | 174 | 1.130 |
Why?
| | HIV-1 | 4 | 2026 | 913 | 1.100 |
Why?
| | Focus Groups | 6 | 2026 | 588 | 1.090 |
Why?
| | Mothers | 7 | 2022 | 772 | 1.080 |
Why?
| | Drug Monitoring | 2 | 2024 | 399 | 1.070 |
Why?
| | Peripartum Period | 2 | 2024 | 19 | 1.010 |
Why?
| | Social Support | 5 | 2024 | 646 | 0.990 |
Why?
| | Transition to Adult Care | 2 | 2026 | 111 | 0.950 |
Why?
| | Female | 58 | 2026 | 79499 | 0.900 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2025 | 272 | 0.890 |
Why?
| | Spouses | 4 | 2020 | 107 | 0.880 |
Why?
| | Prenatal Care | 4 | 2020 | 310 | 0.880 |
Why?
| | Young Adult | 22 | 2026 | 14330 | 0.780 |
Why?
| | Fathers | 1 | 2023 | 53 | 0.760 |
Why?
| | Postpartum Period | 8 | 2025 | 377 | 0.760 |
Why?
| | Zambia | 6 | 2026 | 61 | 0.760 |
Why?
| | Peer Group | 2 | 2024 | 251 | 0.730 |
Why?
| | Humans | 66 | 2026 | 146342 | 0.710 |
Why?
| | Fertilization | 2 | 2026 | 44 | 0.710 |
Why?
| | Patient Navigation | 1 | 2024 | 126 | 0.700 |
Why?
| | Drug Resistance, Viral | 4 | 2026 | 127 | 0.670 |
Why?
| | Interviews as Topic | 3 | 2024 | 930 | 0.650 |
Why?
| | Mentors | 3 | 2021 | 217 | 0.610 |
Why?
| | Adolescent | 23 | 2026 | 22557 | 0.600 |
Why?
| | Adult | 32 | 2026 | 41087 | 0.600 |
Why?
| | Male | 35 | 2026 | 73396 | 0.570 |
Why?
| | Infant, Newborn | 11 | 2026 | 6460 | 0.550 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2026 | 1763 | 0.540 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 298 | 0.540 |
Why?
| | Motivation | 1 | 2022 | 605 | 0.520 |
Why?
| | Heterocyclic Compounds, 3-Ring | 3 | 2026 | 44 | 0.520 |
Why?
| | Child | 23 | 2026 | 22693 | 0.510 |
Why?
| | Health Facilities | 2 | 2021 | 85 | 0.510 |
Why?
| | Health Facility Administration | 1 | 2017 | 8 | 0.500 |
Why?
| | Telemedicine | 2 | 2025 | 966 | 0.500 |
Why?
| | Community Health Services | 2 | 2019 | 229 | 0.500 |
Why?
| | Spouse Abuse | 1 | 2017 | 39 | 0.490 |
Why?
| | Truth Disclosure | 1 | 2017 | 51 | 0.490 |
Why?
| | Reproductive Health Services | 2 | 2026 | 23 | 0.480 |
Why?
| | Reminder Systems | 1 | 2018 | 149 | 0.480 |
Why?
| | Patient Dropouts | 1 | 2016 | 65 | 0.460 |
Why?
| | Patient Acceptance of Health Care | 4 | 2026 | 881 | 0.450 |
Why?
| | HIV Integrase Inhibitors | 2 | 2026 | 80 | 0.430 |
Why?
| | Health Resources | 1 | 2016 | 131 | 0.430 |
Why?
| | Treatment Failure | 4 | 2026 | 361 | 0.420 |
Why?
| | Tuberculosis | 2 | 2014 | 290 | 0.390 |
Why?
| | Point-of-Care Systems | 3 | 2023 | 185 | 0.370 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2026 | 1408 | 0.360 |
Why?
| | Patient Compliance | 1 | 2016 | 589 | 0.350 |
Why?
| | Prospective Studies | 6 | 2025 | 8123 | 0.330 |
Why?
| | Multicenter Studies as Topic | 2 | 2026 | 417 | 0.320 |
Why?
| | Students | 2 | 2026 | 649 | 0.310 |
Why?
| | Colorado | 4 | 2025 | 4595 | 0.310 |
Why?
| | Consultants | 2 | 2026 | 12 | 0.290 |
Why?
| | Child, Preschool | 10 | 2026 | 11913 | 0.290 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1591 | 0.250 |
Why?
| | Trust | 2 | 2026 | 160 | 0.250 |
Why?
| | Lactation | 2 | 2026 | 193 | 0.250 |
Why?
| | Developing Countries | 2 | 2021 | 312 | 0.240 |
Why?
| | Case-Control Studies | 3 | 2018 | 3647 | 0.230 |
Why?
| | Viremia | 1 | 2026 | 158 | 0.220 |
Why?
| | Sexual Behavior | 2 | 2026 | 490 | 0.210 |
Why?
| | Cross-Sectional Studies | 6 | 2026 | 5899 | 0.210 |
Why?
| | Retrospective Studies | 8 | 2024 | 17438 | 0.200 |
Why?
| | United States | 5 | 2026 | 16136 | 0.200 |
Why?
| | Intention | 1 | 2025 | 187 | 0.200 |
Why?
| | Infant Health | 1 | 2023 | 24 | 0.190 |
Why?
| | Risk Factors | 5 | 2025 | 10921 | 0.190 |
Why?
| | Maternal Health | 1 | 2023 | 50 | 0.190 |
Why?
| | RNA, Viral | 2 | 2024 | 693 | 0.190 |
Why?
| | Dried Blood Spot Testing | 1 | 2024 | 129 | 0.190 |
Why?
| | Prevalence | 3 | 2024 | 2861 | 0.190 |
Why?
| | Fear | 1 | 2026 | 373 | 0.190 |
Why?
| | Proportional Hazards Models | 4 | 2024 | 1331 | 0.180 |
Why?
| | CD4 Lymphocyte Count | 2 | 2024 | 280 | 0.180 |
Why?
| | DNA, Viral | 1 | 2024 | 354 | 0.180 |
Why?
| | Telephone | 1 | 2023 | 175 | 0.180 |
Why?
| | Drug Resistance | 1 | 2022 | 145 | 0.170 |
Why?
| | Oxazines | 3 | 2026 | 36 | 0.170 |
Why?
| | Feasibility Studies | 1 | 2025 | 1135 | 0.160 |
Why?
| | Treatment Adherence and Compliance | 1 | 2021 | 27 | 0.160 |
Why?
| | Emigrants and Immigrants | 1 | 2023 | 160 | 0.160 |
Why?
| | Public Health Surveillance | 1 | 2021 | 84 | 0.160 |
Why?
| | Treatment Outcome | 5 | 2021 | 11821 | 0.160 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 40 | 0.160 |
Why?
| | Organophosphates | 1 | 2022 | 179 | 0.160 |
Why?
| | Mass Screening | 2 | 2020 | 1307 | 0.160 |
Why?
| | Reward | 1 | 2022 | 242 | 0.150 |
Why?
| | Infant, Low Birth Weight | 1 | 2021 | 154 | 0.150 |
Why?
| | Pilot Projects | 1 | 2025 | 1888 | 0.150 |
Why?
| | Symptom Assessment | 1 | 2021 | 138 | 0.150 |
Why?
| | Pyridones | 3 | 2026 | 210 | 0.150 |
Why?
| | Patient Participation | 1 | 2023 | 457 | 0.150 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2021 | 238 | 0.150 |
Why?
| | Adenine | 1 | 2022 | 339 | 0.150 |
Why?
| | Health Personnel | 2 | 2023 | 754 | 0.150 |
Why?
| | Piperazines | 3 | 2026 | 368 | 0.140 |
Why?
| | Disclosure | 1 | 2019 | 91 | 0.140 |
Why?
| | C-Reactive Protein | 1 | 2021 | 429 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 738 | 0.140 |
Why?
| | Odds Ratio | 1 | 2021 | 1077 | 0.140 |
Why?
| | Emotions | 1 | 2023 | 559 | 0.130 |
Why?
| | Ambulatory Care | 1 | 2023 | 628 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2026 | 1107 | 0.130 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 109 | 0.130 |
Why?
| | Self Disclosure | 1 | 2017 | 62 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2026 | 6073 | 0.130 |
Why?
| | Research Design | 1 | 2023 | 1143 | 0.130 |
Why?
| | HIV | 1 | 2018 | 249 | 0.130 |
Why?
| | Pregnancy Outcome | 1 | 2021 | 503 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 651 | 0.120 |
Why?
| | Decision Making | 1 | 2024 | 993 | 0.120 |
Why?
| | HIV Seropositivity | 1 | 2017 | 118 | 0.120 |
Why?
| | Comorbidity | 1 | 2021 | 1665 | 0.120 |
Why?
| | Marriage | 1 | 2017 | 122 | 0.110 |
Why?
| | Rural Population | 2 | 2017 | 677 | 0.110 |
Why?
| | Logistic Models | 2 | 2025 | 2126 | 0.110 |
Why?
| | Health Services Research | 1 | 2017 | 390 | 0.100 |
Why?
| | Hospitalization | 2 | 2023 | 2475 | 0.100 |
Why?
| | Attitude of Health Personnel | 2 | 2024 | 1219 | 0.100 |
Why?
| | Isoniazid | 1 | 2014 | 71 | 0.100 |
Why?
| | Biomarkers | 2 | 2024 | 4340 | 0.100 |
Why?
| | Universities | 2 | 2026 | 451 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2921 | 0.090 |
Why?
| | Cohort Studies | 3 | 2024 | 6077 | 0.090 |
Why?
| | Family Characteristics | 2 | 2026 | 203 | 0.090 |
Why?
| | Incidence | 2 | 2022 | 2936 | 0.090 |
Why?
| | Antitubercular Agents | 1 | 2014 | 212 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2018 | 947 | 0.080 |
Why?
| | Nasopharynx | 2 | 2022 | 72 | 0.080 |
Why?
| | Mutation | 1 | 2022 | 4093 | 0.080 |
Why?
| | Depression | 1 | 2020 | 1575 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4351 | 0.070 |
Why?
| | Time Factors | 1 | 2018 | 7109 | 0.060 |
Why?
| | Africa South of the Sahara | 1 | 2026 | 56 | 0.060 |
Why?
| | Lamivudine | 1 | 2026 | 63 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3712 | 0.060 |
Why?
| | Canada | 1 | 2026 | 432 | 0.050 |
Why?
| | Observation | 1 | 2024 | 51 | 0.050 |
Why?
| | Cerebrospinal Fluid | 1 | 2024 | 88 | 0.050 |
Why?
| | Interpersonal Relations | 1 | 2026 | 387 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 617 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2026 | 1036 | 0.050 |
Why?
| | North America | 1 | 2023 | 300 | 0.050 |
Why?
| | Point-of-Care Testing | 1 | 2022 | 36 | 0.050 |
Why?
| | Milk, Human | 1 | 2023 | 176 | 0.040 |
Why?
| | Africa, Northern | 1 | 2021 | 4 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2022 | 173 | 0.040 |
Why?
| | Professional-Patient Relations | 1 | 2022 | 146 | 0.040 |
Why?
| | Oropharynx | 1 | 2020 | 46 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1879 | 0.040 |
Why?
| | Income | 1 | 2021 | 206 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 192 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2026 | 3017 | 0.030 |
Why?
| | Mental Health | 1 | 2025 | 779 | 0.030 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 481 | 0.030 |
Why?
| | House Calls | 1 | 2019 | 154 | 0.030 |
Why?
| | Gene Expression | 1 | 2022 | 1463 | 0.030 |
Why?
| | Delivery, Obstetric | 1 | 2018 | 164 | 0.030 |
Why?
| | Poverty | 1 | 2021 | 530 | 0.030 |
Why?
| | Middle Aged | 3 | 2026 | 36619 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2020 | 561 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1707 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 952 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3416 | 0.020 |
Why?
| | Aged | 1 | 2022 | 26432 | 0.010 |
Why?
|
|
Abuogi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|